These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34877794)

  • 1. A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment.
    Pink A; Krell-Roesch J; Syrjanen JA; Vassilaki M; Lowe VJ; Vemuri P; Stokin GB; Christianson TJ; Kremers WK; Jack CR; Knopman DS; Petersen RC; Geda YE
    Alzheimers Dement; 2022 Oct; 18(10):1824-1831. PubMed ID: 34877794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cortical and Subcortical β-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia.
    Krell-Roesch J; Syrjanen JA; Rakusa M; Vemuri P; Machulda MM; Kremers WK; Mielke MM; Lowe VJ; Jack CR; Knopman DS; Stokin GB; Petersen RC; Vassilaki M; Geda YE
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):64-71. PubMed ID: 33086924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging.
    Krell-Roesch J; Vassilaki M; Mielke MM; Kremers WK; Lowe VJ; Vemuri P; Machulda MM; Christianson TJ; Syrjanen JA; Stokin GB; Butler LM; Traber M; Jack CR; Knopman DS; Roberts RO; Petersen RC; Geda YE
    Transl Psychiatry; 2019 Mar; 9(1):123. PubMed ID: 30923322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging.
    Krell-Roesch J; Lowe VJ; Neureiter J; Pink A; Roberts RO; Mielke MM; Vemuri P; Stokin GB; Christianson TJ; Jack CR; Knopman DS; Boeve BF; Kremers WK; Petersen RC; Geda YE
    Int Psychogeriatr; 2018 Feb; 30(2):245-251. PubMed ID: 29198244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.
    Nadkarni NK; Tudorascu D; Campbell E; Snitz BE; Cohen AD; Halligan E; Mathis CA; Aizenstein HJ; Klunk WE
    J Gerontol A Biol Sci Med Sci; 2019 Oct; 74(11):1753-1760. PubMed ID: 30957843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction.
    Marchant NL; Reed BR; Sanossian N; Madison CM; Kriger S; Dhada R; Mack WJ; DeCarli C; Weiner MW; Mungas DM; Chui HC; Jagust WJ
    JAMA Neurol; 2013 Apr; 70(4):488-95. PubMed ID: 23400560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of brain perfusion SPECT using an easy Z-score imaging system in the mild cognitive impairment subjects with brain amyloid-β deposition.
    Takemaru M; Kimura N; Abe Y; Goto M; Matsubara E
    Clin Neurol Neurosurg; 2017 Sep; 160():111-115. PubMed ID: 28715708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Feru-guard 100M on amyloid-beta deposition in individuals with mild cognitive impairment.
    Matsuyama K; Yamamoto Y; Sora I
    Psychogeriatrics; 2020 Sep; 20(5):726-736. PubMed ID: 32767414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients.
    Almkvist O; Brüggen K; Nordberg A
    J Alzheimers Dis; 2021; 81(4):1613-1624. PubMed ID: 33967046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging.
    Krell-Roesch J; Syrjanen JA; Vassilaki M; Lowe VJ; Vemuri P; Mielke MM; Machulda MM; Stokin GB; Christianson TJ; Kremers WK; Jack CR; Knopman DS; Petersen RC; Geda YE
    Am J Geriatr Psychiatry; 2021 Feb; 29(2):179-191. PubMed ID: 32646634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.
    Beckett TL; Webb RL; Niedowicz DM; Holler CJ; Matveev S; Baig I; LeVine H; Keller JN; Murphy MP
    J Alzheimers Dis; 2012; 32(1):127-38. PubMed ID: 22766739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfaction, Cognitive Impairment, and PET Biomarkers in Community-Dwelling Older Adults.
    Tian Q; Bilgel M; Moghekar AR; Ferrucci L; Resnick SM
    J Alzheimers Dis; 2022; 86(3):1275-1285. PubMed ID: 35180111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Zhang N; Zhang L; Li Y; Gordon ML; Cai L; Wang Y; Xing M; Cheng Y
    J Alzheimers Dis; 2017; 60(1):87-95. PubMed ID: 28777752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.